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Target population in Spain is estimated at 500,000 patients and
15% of those receive a monoterapia drug treatment for acute
bipolar mania. Nowadays, when considering drug costs, direct
medical costs and adverse events treatment, average annual cost
per treated patient in Spain is estimated at €4006 and it is likely
to be estimated at €4039 after the introduction of ziprasidone.
Sensibility analysis showed that at a constant market share of
24% for the forecasted three years, then the introduction of
ziprasidone is not likely to have any economic impact on the
Spanish National Pharmaceutical budget. CONCLUSIONS:
This budget impact model shows that the introduction of ziprasi-
done is likely to have minimal impact on acute bipolar mania
medication costs in Spain. Current drug costs due to acute
bipolar mania were estimated at €908 millions for the next 3
years and at €916 millions after the introduction of ziprasidone.
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ADHD is a common disorder of childhood and adolescence in
the US and Europe. The NIMH MTA Study is a clinical land-
mark trial, including 579 children age 7–9.9 years with ADHD
according to DSM-IV criteria, who were randomly assigned to
14 months of medication management (MedMgt), intense behav-
ioral treatment (Beh), both combined (Comb), or community care
(CC). OBJECTIVE: To evaluate the cost-effectiveness of clinically
proven treatment strategies (neither placebo nor single drugs) for
ADHD and Hyperkinetic Disorder (HKD/HKCD, a subgroup
meeting ICD-10-based diagnostic criteria used in Europe) in ﬁve
countries, using patient-level data from the MTA Study over 14
months. METHODS: Medical resource utilization data came
from the MTA, excluding its research component. Unit costs (year
2005) were calculated from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, UK,
and USA. Corresponding to the primary study endpoint, treat-
ment response was deﬁned as normalization of core symptoms
(SNAP-IV teacher/parent scores <1). Utility estimates were
derived from expert estimates and parent-proxy-ratings.
RESULTS: Incremental cost-effectiveness ratios (ICERs) were
determined for the total study population and subgroups with
pure ADHD (without comorbidity, n = 184), pure HKD (n = 77),
or HKD/HKCD (n = 145). ICERs per additional patient “nor-
malized” ranged from to dominance to €4200 for MedMgt versus
CC and from €21,000 to €100,000 for Comb versus MedMgt.
MedMgt dominated Beh and exhibited extended dominance over
CC compared to a hypothetical “Do Nothing” alternative.
Results were supported by cost-effectiveness acceptability and
sensitivity analyses. CONCLUSIONS: Despite international dif-
ferences regarding standards of care, diagnostic criteria, and unit
costs, key ﬁndings for European jurisdictions were consistent with
US results. Although cost-utility estimates for this pediatric pop-
ulation should be interpreted with caution, results indicate accept-
able to attractive cost-effectiveness of an intense MedMgt
strategy. Further analyses will have to explore the impact of psy-
chiatric comorbidity and broader clinical endpoints.
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Beyond disease-deﬁning core symptoms of inattention, hyperac-
tivity, and impulsivity, ADHD is characterized by functional
impairment of patients. The Columbia Impairment Scale (CIS) is
a parent rating scale with relatively strong psychometric prop-
erties, tapping four major dimensions: interpersonal relations,
psychopathology, schoolwork, and use of leisure time. OBJEC-
TIVES: CIS ratings from the NIMH MTA Study (n = 579 chil-
dren with ADHD according to DSM-IV-criteria) were used as an
alternative outcome measure to evaluate the cost-effectiveness of
medication management (MedMgt), intense behavioral treat-
ment (Beh), both combined (Comb), or community care (CC) in
the study population and in three subgroups: hyperkinetic dis-
order (according to ICD-10-criteria preferred in Europe); pure
HKD or HKD/HKCD, and in pure ADHD, over 14 months.
METHODS: For costing (societal and third-party payer’s per-
spectives), patient-level resource utilization data were combined
with country-speciﬁc unit costs for Germany, The Netherlands,
Sweden, UK, and United States (year 2005). Incremental cost-
effectiveness ratios (ICERs) were determined using functional
improvement (CIS effect size [ES], Cohen’s d) as clinical outcome
criterion. Four treatment strategies and a hypothetical “Do
Nothing” alternative were compared with each other. RESULTS:
The four MTA treatment strategies were all clinically effective.
Across jurisdictions, both CC versus “Do Nothing” (ICERs
ranging from €1200/ES to €2600/ES) and MedMgt (ICERs
versus “Do Nothing” from €1000/ES to €2700/ES, ICERs versus
CC from dominance to €3000/ES) appeared attractive on
grounds of cost-effectiveness. MedMgt dominated Beh, and
ICERs for Comb versus MedMgt ranged from €500,000/ES to
€1,000,000/ES. Results for subgroups with pure ADHD,
HKD/HKCD, and pure HKD were broadly similar. Sensitivity
analyses including probabilistic evaluations using non-paramet-
ric bootstrapping supported these ﬁndings. CONCLUSIONS:
Despite notable international differences in terms of diagnostic
criteria, standards of care, and unit costs, the cost-effectiveness
of MTA-based clinical treatment strategies for patients with pure
ADHD seemed remarkably similar across jurisdictions. The
impact of comorbidity remains to be explored.
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OBJECTIVE: In light of recent clinical evidence, the indication
of the NMDA antagonist memantine has been extended to
“moderate to severe Alzheimer’s disease (AD)”. No pharmaco-
economic evaluation has been performed in this indication to
